Fulcrum Therapeutics (FULC) Return on Equity: 2020-2025
Historic Return on Equity for Fulcrum Therapeutics (FULC) over the last 4 years, with Sep 2025 value amounting to -0.37%.
- Fulcrum Therapeutics' Return on Equity fell 30.00% to -0.37% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.37%, marking a year-over-year decrease of 30.00%. This contributed to the annual value of -0.04% for FY2024, which is 41.00% up from last year.
- As of Q3 2025, Fulcrum Therapeutics' Return on Equity stood at -0.37%, which was down 15,787.18% from -0.00% recorded in Q2 2025.
- In the past 5 years, Fulcrum Therapeutics' Return on Equity ranged from a high of -0.00% in Q2 2025 and a low of -0.62% during Q1 2021.
- In the last 3 years, Fulcrum Therapeutics' Return on Equity had a median value of -0.36% in 2023 and averaged -0.26%.
- In the last 5 years, Fulcrum Therapeutics' Return on Equity surged by 36bps in 2024 and then decreased by 30bps in 2025.
- Quarterly analysis of 5 years shows Fulcrum Therapeutics' Return on Equity stood at -0.37% in 2021, then fell by 16bps to -0.52% in 2022, then grew by 13bps to -0.40% in 2023, then spiked by 36bps to -0.04% in 2024, then fell by 30bps to -0.37% in 2025.
- Its Return on Equity stands at -0.37% for Q3 2025, versus -0.00% for Q2 2025 and -0.04% for Q4 2024.